---
title: "Transthera wins China NMPA clearance for Phase II TT-00973 combo trial in EGFR-mutant NSCLC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292332316.md"
description: "Transthera Sciences received China NMPA clearance to initiate a Phase II trial of TT-00973 combined with firmonertinib for EGFR-mutant NSCLC. The multicenter study targets locally advanced or metastatic disease, with Shanghai Allist Pharmaceuticals supplying the drug under a May 2026 collaboration. Partners aim to evaluate a potential Phase III program based on these results."
datetime: "2026-07-10T14:18:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292332316.md)
  - [en](https://longbridge.com/en/news/292332316.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292332316.md)
generator: "portal-rs"
---

# Transthera wins China NMPA clearance for Phase II TT-00973 combo trial in EGFR-mutant NSCLC

-   Transthera Sciences won China NMPA clearance to start a Phase II trial of TT-00973 tablets with firmonertinib in EGFR-mutant NSCLC. \* The multicenter, open-label study targets locally advanced or metastatic disease. \* Shanghai Allist Pharmaceuticals will supply firmonertinib under a clinical collaboration signed in May 2026. \* The partners plan to assess a potential Phase III program based on the Phase II results. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences (Nanjing) Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260710-12241841), on July 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [688578.CN](https://longbridge.com/en/quote/688578.CN.md)
- [02617.HK](https://longbridge.com/en/quote/02617.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [04:03 ETDizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026](https://longbridge.com/en/news/296585269.md)
- [China Shenhua signs start notice for TT mine expansion exploration in Mongolia](https://longbridge.com/en/news/296561021.md)
- [If You Invested $100 In Trane Technologies Stock 5 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/296268226.md)
- [CStone says China NMPA clears IND for CS5007 EGFR/HER3 bispecific ADC](https://longbridge.com/en/news/296540686.md)
- [Fuyao lists a solar sunroof capable of producing 150 watts per square meter](https://longbridge.com/en/news/296744078.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**